BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gamie Z, Kapriniotis K, Papanikolaou D, Haagensen E, Da Conceicao Ribeiro R, Dalgarno K, Krippner-Heidenreich A, Gerrand C, Tsiridis E, Rankin KS. TNF-related apoptosis-inducing ligand (TRAIL) for bone sarcoma treatment: Pre-clinical and clinical data. Cancer Lett 2017;409:66-80. [PMID: 28888998 DOI: 10.1016/j.canlet.2017.08.036] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]
Number Citing Articles
1 Li J, Li X, Zhou S, Wang Y, Lu Y, Wang Q, Zhao F. Tetrandrine inhibits RANKL-induced osteoclastogenesis by promoting the degradation of TRAIL. Mol Med 2022;28:141. [DOI: 10.1186/s10020-022-00568-4] [Reference Citation Analysis]
2 Li L, Yang M, Yu J, Cheng S, Ahmad M, Wu C, Wan X, Xu B, Ben-David Y, Luo H. A Novel L-Phenylalanine Dipeptide Inhibits the Growth and Metastasis of Prostate Cancer Cells via Targeting DUSP1 and TNFSF9. Int J Mol Sci 2022;23:10916. [PMID: 36142828 DOI: 10.3390/ijms231810916] [Reference Citation Analysis]
3 Zhuang J, Zu J, Zhou C, Sun Y, Kong P, Jing Y, Acharya A. Bioinformatic Data Mining for Candidate Drugs Affecting Risk of Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ) in Cancer Patients. Disease Markers 2022;2022:1-10. [DOI: 10.1155/2022/3348480] [Reference Citation Analysis]
4 Fayzullina D, Tsibulnikov S, Stempen M, Schroeder BA, Kumar N, Kharwar RK, Acharya A, Timashev P, Ulasov I. Novel Targeted Therapeutic Strategies for Ewing Sarcoma. Cancers 2022;14:1988. [DOI: 10.3390/cancers14081988] [Reference Citation Analysis]
5 Peng H, Guo X, He J, Duan C, Yang M, Zhang X, Zhang L, Fu R, Wang B, Wang D, Chen H, Xie M, Feng P, Dai L, Tang X, Luo J. Intracranial delivery of synthetic mRNA to suppress glioblastoma. Mol Ther Oncolytics 2022;24:160-70. [PMID: 35024442 DOI: 10.1016/j.omto.2021.12.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
6 Sun J, Xu H, Lei Z, Li Z, Zhu H, Deng Z, Yu X, Jin X, Yang Z. The lncRNA CASC2 Modulates Hepatocellular Carcinoma Cell Sensitivity and Resistance to TRAIL Through Apoptotic and Non-Apoptotic Signaling. Front Oncol 2022;11:726622. [DOI: 10.3389/fonc.2021.726622] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Richter G, Lissat A, Kontny U. Regulated cell death and drug resistance in malignant bone tumors. Bone Cancer 2022. [DOI: 10.1016/b978-0-12-821666-8.00055-4] [Reference Citation Analysis]
8 Qi Z, Le Z, Han F, Feng Y, Yang M, Ji C, Zhao L. Inhibitory regulation of purple sweet potato polysaccharide on the hepatotoxicity of tri-(2,3-dibromopropyl) isocyanate. Int J Biol Macromol 2022;194:445-51. [PMID: 34813788 DOI: 10.1016/j.ijbiomac.2021.11.086] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Hua X, Wu P, Gao GS, Ye XL. Combination of oridonin and TRAIL induces apoptosis in uveal melanoma cells by upregulating DR5. Int J Ophthalmol 2021;14:1834-42. [PMID: 34926196 DOI: 10.18240/ijo.2021.12.05] [Reference Citation Analysis]
10 Sarhadi VK, Daddali R, Seppänen-Kaijansinkko R. Mesenchymal Stem Cells and Extracellular Vesicles in Osteosarcoma Pathogenesis and Therapy. Int J Mol Sci 2021;22:11035. [PMID: 34681692 DOI: 10.3390/ijms222011035] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
11 Vasella M, Gousopoulos E, Guidi M, Storti G, Song SY, Grieb G, Pauli C, Lindenblatt N, Giovanoli P, Kim BS. Targeted Therapies and Checkpoint Inhibitors in Sarcoma. QJM 2021:hcab014. [PMID: 33486519 DOI: 10.1093/qjmed/hcab014] [Reference Citation Analysis]
12 Fu P, Shi Y, Chen G, Fan Y, Gu Y, Gao Z. Prognostic Factors in Patients With Osteosarcoma With the Surveillance, Epidemiology, and End Results Database. Technol Cancer Res Treat 2020;19:1533033820947701. [PMID: 32787692 DOI: 10.1177/1533033820947701] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
13 Lohberger B, Bernhart E, Stuendl N, Glaenzer D, Leithner A, Rinner B, Bauer R, Kretschmer N. Periplocin mediates TRAIL-induced apoptosis and cell cycle arrest in human myxofibrosarcoma cells via the ERK/p38/JNK pathway. Phytomedicine 2020;76:153262. [PMID: 32559583 DOI: 10.1016/j.phymed.2020.153262] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
14 Lin L, Ding D, Xiao X, Li B, Cao P, Li S. Trametinib potentiates TRAIL-induced apoptosis via FBW7-dependent Mcl-1 degradation in colorectal cancer cells. J Cell Mol Med 2020;24:6822-32. [PMID: 32352219 DOI: 10.1111/jcmm.15336] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
15 Dianat-Moghadam H, Heidarifard M, Mahari A, Shahgolzari M, Keshavarz M, Nouri M, Amoozgar Z. TRAIL in oncology: From recombinant TRAIL to nano- and self-targeted TRAIL-based therapies. Pharmacol Res 2020;155:104716. [PMID: 32084560 DOI: 10.1016/j.phrs.2020.104716] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 11.5] [Reference Citation Analysis]
16 Wang J, Liu S, Shi J, Li J, Wang S, Liu H, Zhao S, Duan K, Pan X, Yi Z. The Role of miRNA in the Diagnosis, Prognosis, and Treatment of Osteosarcoma. Cancer Biother Radiopharm 2019;34:605-13. [PMID: 31674804 DOI: 10.1089/cbr.2019.2939] [Cited by in Crossref: 45] [Cited by in F6Publishing: 51] [Article Influence: 15.0] [Reference Citation Analysis]
17 Dai H, Jiang Y, Luo Y, Bie P, Chen Z. Triptolide enhances TRAIL sensitivity of pancreatic cancer cells by activating autophagy via downregulation of PUM1. Phytomedicine 2019;62:152953. [PMID: 31128486 DOI: 10.1016/j.phymed.2019.152953] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
18 Carmagnani Pestana R, Groisberg R, Roszik J, Subbiah V. Precision Oncology in Sarcomas: Divide and Conquer. JCO Precis Oncol 2019;3:PO. [PMID: 32914012 DOI: 10.1200/PO.18.00247] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
19 Bhutia SK, Panda PK, Sinha N, Praharaj PP, Bhol CS, Panigrahi DP, Mahapatra KK, Saha S, Patra S, Mishra SR, Behera BP, Patil S, Maiti TK. Plant lectins in cancer therapeutics: Targeting apoptosis and autophagy-dependent cell death. Pharmacol Res 2019;144:8-18. [PMID: 30951812 DOI: 10.1016/j.phrs.2019.04.001] [Cited by in Crossref: 58] [Cited by in F6Publishing: 52] [Article Influence: 19.3] [Reference Citation Analysis]
20 Stamatopoulos A, Stamatopoulos T, Gamie Z, Kenanidis E, Ribeiro RDC, Rankin KS, Gerrand C, Dalgarno K, Tsiridis E. Mesenchymal stromal cells for bone sarcoma treatment: Roadmap to clinical practice. J Bone Oncol 2019;16:100231. [PMID: 30956944 DOI: 10.1016/j.jbo.2019.100231] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
21 Jiang Z, Jiang J, Ma Y, Li H, Shi W, Fu P, Xu C, Lu J, Fu D, Xu J. Downregulation of miR-223 and miR-19a induces differentiation and promotes recruitment of osteoclast cells in giant-cell tumor of the bone via the Runx2/TWIST-RANK/RANKL pathway. Biochemical and Biophysical Research Communications 2018;505:1003-9. [DOI: 10.1016/j.bbrc.2018.10.025] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
22 Lohberger B, Wagner S, Wohlmuther J, Kaltenegger H, Stuendl N, Leithner A, Rinner B, Kunert O, Bauer R, Kretschmer N. Periplocin, the most anti-proliferative constituent of Periploca sepium, specifically kills liposarcoma cells by death receptor mediated apoptosis. Phytomedicine 2018;51:162-70. [PMID: 30466613 DOI: 10.1016/j.phymed.2018.10.008] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
23 Nazeri E, Gouran Savadkoohi M, Majidzadeh-A K, Esmaeili R. Chondrosarcoma: An overview of clinical behavior, molecular mechanisms mediated drug resistance and potential therapeutic targets. Crit Rev Oncol Hematol 2018;131:102-9. [PMID: 30293700 DOI: 10.1016/j.critrevonc.2018.09.001] [Cited by in Crossref: 36] [Cited by in F6Publishing: 41] [Article Influence: 9.0] [Reference Citation Analysis]
24 Gallego-Lleyda A, De Miguel D, Anel A, Martinez-Lostao L. Lipid Nanoparticles Decorated with TNF-Related Aptosis-Inducing Ligand (TRAIL) Are More Cytotoxic than Soluble Recombinant TRAIL in Sarcoma. Int J Mol Sci 2018;19:E1449. [PMID: 29757258 DOI: 10.3390/ijms19051449] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
25 Birley K, Chester K, Anderson J. Antibody based therapy for childhood solid cancers. Current Opinion in Chemical Engineering 2018;19:153-162. [DOI: 10.1016/j.coche.2018.01.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]